{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T13:18:45Z","timestamp":1719062325285},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02755-6","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T15:02:02Z","timestamp":1686841322000},"page":"3499-3507","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab"],"prefix":"10.1007","volume":"43","author":[{"given":"Malgorzata","family":"Woronkowicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Lightman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Zagora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Tomkins-Netzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"5","key":"2755_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","volume":"31","author":"K Neelam","year":"2012","unstructured":"Neelam K, Cheung CMG, Ohno-Matsui K, Lai TYY, Wong TY (2012) Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 31(5):495\u2013525","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"2755_CR2","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","volume":"103","author":"SY Cohen","year":"1996","unstructured":"Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103(8):1241\u20131244","journal-title":"Ophthalmology"},{"key":"2755_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","volume":"63","author":"K Ohno-Matsui","year":"2018","unstructured":"Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92\u2013106","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"2755_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1097\/IAE.0000000000001456","volume":"37","author":"E Bruy\u00e8re","year":"2017","unstructured":"Bruy\u00e8re E, Miere A, Cohen SY et al (2017) Neovascularization secondary to high myopia imaged by optical coherence tomography angiography. Retina 37(11):2095\u20132101","journal-title":"Retina"},{"issue":"3","key":"2755_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G et al (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682\u201392.e2","journal-title":"Ophthalmology"},{"issue":"6","key":"2755_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY et al (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220\u20131227","journal-title":"Ophthalmology"},{"issue":"12","key":"2755_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","volume":"121","author":"O Tomkins-Netzer","year":"2014","unstructured":"Tomkins-Netzer O, Talat L, Bar A et al (2014) Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 121(12):2387\u20132392","journal-title":"Ophthalmology"},{"key":"2755_CR8","unstructured":"WHO (2017) Change the definition of blindness. Available at: who.int\/blindness\/ [Accessed May 17, 2017]"},{"key":"2755_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","volume":"52","author":"K Ohno-Matsui","year":"2016","unstructured":"Ohno-Matsui K, Lai TYY, Lai C-C, Cheung CMG (2016) Updates of pathologic myopia. Prog Retin Eye Res 52:156\u2013187","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"2755_CR10","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","unstructured":"Macular Photocoagulation Study Group (1991) Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109(9):1220\u20131231","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"2755_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","volume":"159","author":"K Ohno-Matsui","year":"2015","unstructured":"Ohno-Matsui K, Kawasaki R, Jonas JB et al (2015) International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 159(5):877\u201383.e7","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2755_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","volume":"149","author":"M Gharbiya","year":"2010","unstructured":"Gharbiya M, Giustolisi R, Allievi F et al (2010) Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab\u2013a randomized controlled trial. Am J Ophthalmol 149(3):458\u201364.e1","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"2755_CR13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00417-014-2886-x","volume":"253","author":"A Pece","year":"2015","unstructured":"Pece A, Milani P, Monteleone C et al (2015) A randomized trial of intravitreal bevacizumab vs ranibizumab for myopic CNV. Graefe\u2019s Arch Clin Exp Ophthalmol = Albr von Graefes Arch fur Klin und Exp Ophthalmol 253(11):1867\u20131872","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol = Albr von Graefes Arch fur Klin und Exp Ophthalmol"},{"key":"2755_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1471-2415-14-69","volume":"14","author":"DM Cha","year":"2014","unstructured":"Cha DM, Kim TW, Heo JW et al (2014) Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmol 14:69","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"2755_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","volume":"32","author":"P Iacono","year":"2012","unstructured":"Iacono P, Parodi MB, Papayannis A et al (2012) Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 32(8):1539\u20131546","journal-title":"Retina"},{"issue":"6","key":"2755_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","volume":"156","author":"HS Yang","year":"2013","unstructured":"Yang HS, Kim J-G, Kim JT, Joe SG (2013) Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol 156(6):1201-1210.e2","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"2755_CR17","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/eye.2012.97","volume":"26","author":"TYY Lai","year":"2012","unstructured":"Lai TYY, Luk FOJ, Lee GKY, Lam DSC (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 26(7):1004\u20131011","journal-title":"Eye (Lond)"},{"issue":"12","key":"2755_CR18","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","volume":"35","author":"DS-C Ng","year":"2015","unstructured":"Ng DS-C, Kwok AKH, Tong JM-K, Chan CW-N, Li WW-T (2015) Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina 35(12):2457\u20132468","journal-title":"Retina"},{"issue":"8","key":"2755_CR19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/bjophthalmol-2012-301639","volume":"96","author":"M Gharbiya","year":"2012","unstructured":"Gharbiya M, Cruciani F, Parisi F, Cuozzo G, Altimari S, Abdolrahimzadeh S (2012) Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 96(8):1068\u20131072","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"2755_CR20","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.ophtha.2014.06.012","volume":"121","author":"L Ceklic","year":"2014","unstructured":"Ceklic L, Wolf-Schnurrbusch U, Gekkieva M, Wolf S (2014) Visual acuity outcome in RADIANCE study patients with dome-shaped macular features. Ophthalmology 121(11):2288\u20132289","journal-title":"Ophthalmology"},{"issue":"3","key":"2755_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/eye.2016.249","volume":"31","author":"JH Lee","year":"2017","unstructured":"Lee JH, Lee SC, Choi S, Koh HJ, Kim SS, Lee CS (2017) Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization associated with a dome-shaped macula in pathologic myopia. Eye (Lond) 31(3):507\u2013508","journal-title":"Eye (Lond)"},{"issue":"4","key":"2755_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000357290","volume":"231","author":"CL Farinha","year":"2014","unstructured":"Farinha CL, Baltar AS, Nunes SG et al (2014) Progression of myopic maculopathy after treatment of choroidal neovascularization. Ophthalmol J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd 231(4):211\u2013220","journal-title":"Ophthalmol J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd"},{"issue":"8","key":"2755_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","volume":"90","author":"GR Hampton","year":"1983","unstructured":"Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90(8):923\u2013926","journal-title":"Ophthalmology"},{"issue":"4","key":"2755_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","volume":"32","author":"K Hayashi","year":"2012","unstructured":"Hayashi K, Shimada N, Moriyama M, Hayashi W, Tokoro T, Ohno-Matsui K (2012) Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 32(4):687\u2013695","journal-title":"Retina"},{"issue":"1","key":"2755_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","volume":"147","author":"Y Ikuno","year":"2009","unstructured":"Ikuno Y, Sayanagi K, Soga K et al (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147(1):94-100.e1","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2755_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/IAE.0000000000001236","volume":"37","author":"L Ceklic","year":"2017","unstructured":"Ceklic L, Munk MR, Wolf-Schnurrbusch U, Gekkieva M, Wolf S (2017) Visual acuity outcomes of ranibizumab treatment in pathologic myopic eyes with macular retinoschisis and choroidal neovascularization. Retina 37(4):687\u2013693","journal-title":"Retina"},{"issue":"1","key":"2755_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jcjo.2011.12.009","volume":"47","author":"E Peiretti","year":"2012","unstructured":"Peiretti E, Vinci M, Fossarello M (2012) Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 47(1):28\u201333","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"2755_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/IAE.0000000000000332","volume":"35","author":"S Goto","year":"2015","unstructured":"Goto S, Sayanagi K, Ikuno Y, Jo Y, Gomi F, Nishida K (2015) Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up. Retina 35(3):429\u2013434","journal-title":"Retina"},{"issue":"5","key":"2755_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/IAE.0b013e3181f2a293","volume":"31","author":"T Wakabayashi","year":"2011","unstructured":"Wakabayashi T, Ikuno Y, Gomi F (2011) Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina 31(5):880\u2013886","journal-title":"Retina"},{"issue":"6","key":"2755_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/eye.2009.88","volume":"23","author":"JM Mon\u00e9s","year":"2009","unstructured":"Mon\u00e9s JM, Amselem L, Serrano A, Garcia M, Hijano M (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 23(6):1275\u20131280","journal-title":"Eye (Lond)"},{"issue":"2","key":"2755_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/jop.2011.0106","volume":"28","author":"T-T Wu","year":"2012","unstructured":"Wu T-T, Kung Y-H (2012) The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 28(2):129\u2013133","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02755-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:13:23Z","timestamp":1694772803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["2755"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02755-6","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: Robin Hamilton received payment for lectures including service on speaker bureaus from Novartis, Bayer and Allergan. Oren Tomkins-Netzer received payment for consultancy from Abbvie inc.\nNon-financial interests: none","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Robin Hamilton received payment for lectures including service on speaker bureaus from Novartis, Bayer and Allergan. Oren Tomkins\u2013Netzer received payment for consultancy from Abbvie inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study received Institutional Review Board approval and was conducted in accordance with the tenets of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}